Simulations Plus Inc (FRA:SD3) Stock Price, Trades & News

Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

Financial Strength

8/10

Name	Current	Vs Industry	Vs History
Cash-To-Debt	82.35
Equity-to-Asset	0.91
Debt-to-EBITDA	0.03
Interest Coverage	N/A	N/A	N/A
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	16.77	Distress Grey Safe
Beneish M-Score	-3.06	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	14.9
	3-Year EBITDA Growth Rate	-6.4
	3-Year EPS without NRI Growth Rate	-18.6
	3-Year FCF Growth Rate	2.2
	3-Year Book Growth Rate	-11
	Future 3-5Y Total Revenue Growth Rate Estimate	5.36

Momentum Rank

1/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	70.43
	9-Day RSI	68.35
	14-Day RSI	65.57
	3-1 Month Momentum %	38.61
	6-1 Month Momentum %	-9.09
	12-1 Month Momentum %	-62.16

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	5.47
	Quick Ratio	5.47
	Cash Ratio	3.39
	Days Sales Outstanding	64.64
	Days Payable	11.93

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	0.2
	Shareholder Yield %	0.11

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	61.97
	Operating Margin %	12.41
	Net Margin %	-77.96
	EBITDA Margin %	20.57
	FCF Margin %	25.86
	OCF Margin %	30.35
	ROE %	-44.91
	ROA %	-41.74
	ROIC %	8.16
	3-Year ROIIC %	-16.14
	ROC (Joel Greenblatt) %	68.26
	ROCE %	7.12
	Years of Profitability over Past 10-Year	9
	Moat Score	5
	Tariff Resilience Score	8

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	Forward PE Ratio	33
	PE Ratio without NRI	20.42
	Shiller PE Ratio	100.58
	PS Ratio	4.61
	PB Ratio	2.78
	Price-to-Tangible-Book	6.01
	Price-to-Free-Cash-Flow	17.84
	Price-to-Operating-Cash-Flow	15.2
	EV-to-EBIT	33.03
	EV-to-EBITDA	19.94
	EV-to-Revenue	4.1
	EV-to-Forward-Revenue	4.7
	EV-to-FCF	15.9
	Price-to-GF-Value	0.48
	Price-to-Projected-FCF	1.4
	Price-to-Median-PS-Value	0.34
	Price-to-Graham-Number	2.33
	Price-to-Net-Current-Asset-Value	6.78
	Price-to-Net-Cash	12.74
	Earnings Yield (Greenblatt) %	3.03
	FCF Yield %	5.59
	Forward Rate of Return (Yacktman) %	-0.25

Financials (Next Earnings Date:2026-07-14 Est.)

Annual Quarterly TTM

FRA:SD3's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Simulations Plus Inc Operating Data

Annual Quarterly

FRA:SD3's Complete Operating Data

No operating data available for Simulations Plus Inc.

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Simulations Plus Inc Executives

Details

GF Value™: €32.93

FRA:SD3

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 4 Severe warning signs with SD3. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	69.544
	EPS (TTM) (€)	-2.785
	Beta	0.551
	3-Year Sharpe Ratio	-0.08
	3-Year Sortino Ratio	-0.11
	Volatility %	75.2
	14-Day RSI	65.57
	14-Day ATR (€)	0.257102
	20-Day SMA (€)	15.02
	12-1 Month Momentum %	-62.16
	52-Week Range (€)	9.55 - 37
	Shares Outstanding (Mil)	20.22

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	6
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Simulations Plus Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Simulations Plus Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Fourth quarter earnings conference call for 2026	2026-12-01 17:00	In 150 days
Annual report for 2026	2026-12-01	In 149 days
Fourth quarter earnings results for 2026	2026-12-01	In 149 days
Third quarter earnings conference call for 2026	2026-07-14 17:00	In 10 days
Third quarter earnings results for 2026	2026-07-14	In 9 days
Project Optimus: Oncology Dose Optimization Based on Clinical Pharmacology Strategy and MIDD Approach	2026-05-26 11:00	13.20 (+0.00%)
Second quarter earnings conference call for 2026	2026-04-09 17:00	10.90 (+0.00%)
Second quarter earnings results for 2026	2026-04-09	10.90 (+0.00%)
General meeting for 2025	2026-02-12 14:00	11.60 (+0.00%)
Clinical Pharmacology Considerations and Modeling of CAR-T Cell Therapies Using Monolix	2026-01-22 11:00	17.20 (+0.00%)

Show

Entries

Simulations Plus Inc Frequently Asked Questions

What is Simulations Plus Inc(FRA:SD3)'s stock price today?

The current price of FRA:SD3 is €15.80. The 52 week high of FRA:SD3 is €37.00 and 52 week low is €9.55.

When is next earnings date of Simulations Plus Inc(FRA:SD3)?

The next earnings date of Simulations Plus Inc(FRA:SD3) is 2026-07-14 Est..

Does Simulations Plus Inc(FRA:SD3) pay dividends? If so, how much?

Simulations Plus Inc(FRA:SD3) does not pay dividend.

Press Release

	Subject	Date
	Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel	2026-07-01
	Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel	2026-06-24
	Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit	2026-06-23
	Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel	2026-06-22
	SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Simulations Plus, Inc. (NASDAQ: SLP)	2026-06-18
	SLP Investors Have Opportunity to Join Simulations Plus, Inc. Fraud Investigation with the Schall Law Firm	2026-06-16
	SLP Stock Alert: Halper Sadeh LLC is Investigating Whether Simulations Plus, Inc. is Obtaining a Fair Price for its Shareholders	2026-06-16
	Shareholder Alert: Ademi LLP investigates whether Simulations Plus, Inc. is obtaining a Fair Price for Public Shareholders	2026-06-16
	Simulations Plus to Be Acquired by Altaris For Approximately $375 Million	2026-06-16
	SLP INVESTIGATION ALERT: Johnson Fistel Continues Investigation of Simulations Plus, Inc. Following Guidance Cut, Impairment Charge, and Auditor Disclosures	2026-06-15

10/Page

Articles on Simulations Plus Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.